HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: L'Oreal/Maybelline merger

This article was originally published in The Rose Sheet

Executive Summary

L'Oreal/Maybelline merger: Department of Justice's Antitrust division will "raise no objection to L'Oreal's acquisition of Maybelline," the Paris-based firm announced Feb. 8, one day before L'Oreal S.A.'s cash tender offer of $44 per share for all Maybelline's outstanding common shares was set to expire. The previous Feb. 2 deadline had been extended to Feb. 9 at the request of DOJ, which was reviewing information about the proposed merger ("The Rose Sheet" Feb. 5, In Brief). As of Feb. 7, about 63% of Maybelline's approximately 14 mil. shares outstanding had been tendered, L'Oreal said. Separately, in a move to deter a hostile takeover, Maybelline adopted a stockholder rights plan Feb. 2 to "ensure the continued orderly sales process." The plan "will not interfere with" L'Oreal's proposed purchase or "prevent any other business combination transaction approved by Maybelline's Board of Directors," Maybelline noted. The rights issued under the plan initially will trade together with Maybelline's common shares and will only be excercisable under limited conditions, including the purchase of 10% or more of Maybelline's common shares, subject to certain exceptions, the firm said...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel